Developing tests to ensure the safety of gene editing therapies
Official title: Validated Immunoassays to Accelerate Therapeutic Genome Editing INDs
Funded at University of California at Davis · NIH-11145386 · Data updated 2026-11-12
This study is working on new tests to check how your immune system reacts to gene editing treatments before they are given to people, helping to make sure these therapies are safe and effective.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project start | May 22, 2025 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $715,222 |
| NIH project number | 1U01AI191209-01 |
| Project ID | NIH-11145386 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with conditions that may benefit from gene editing therapies, such as genetic disorders or certain cancers.
✕Less likely to help
Patients who do not have conditions that could be treated with gene editing therapies may not receive any benefit from this research.
What this research studies
This research focuses on creating validated immunoassays to monitor the immune response to gene editing therapies before they are tested in humans. By using advanced techniques like cytokine flow cytometry and multiplex immunoassays, the study aims to measure T-cell immunity and antibody responses to gene editing proteins. This will help ensure the safety and effectiveness of these therapies as they move from laboratory studies to clinical trials. The research will also utilize imaging techniques to track immune responses in living organisms.
Why it matters
Potential benefit: If successful, this research could lead to safer gene editing therapies for a variety of diseases.
How similar studies have gone: Previous research has shown promise in using immunoassays for monitoring immune responses in gene therapy, indicating that this approach is both relevant and potentially effective.
Where this research is happening
-
University of California at Davis
Davis, United States Active
Researchers
- Principal investigator: Tarantal, Alice F — University of California at Davis
- Study coordinator: Tarantal, Alice F
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.